What is Rapport Therapeutics, Inc.'s preferred stock?

Rapport Therapeutics, Inc. (RAPP) reported preferred stock of $0 in Q1 2026.

What does preferred stock mean?

Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.

Rapport Therapeutics, Inc. RAPP Preferred Stock

Preferred Stock at other companies

Praxis Precision Medicines, Inc.PRAX

$0—

BiohavenBHVN

$0—

PVL

Palvella TherapeuticsPVLA

$0—

Acadia PharmaceuticalsACAD

$0—

Catalyst PharmaceuticalCPRX

$0—

Relay Therapeutics, Inc.RLAY

$0—

Other financials

Income statement

See full

Revenue$20.0M—

Operating income-$24.2M+10.7%

Net income-$19.9M+17.5%

EPS (diluted)-$0.42+38.2%

Balance sheet

See full

Cash & equivalents$78.1M+35.5%

Total debt$10.8M+37.8%

Total equity$471.5M+65.0%

Total assets$497.6M+64.7%

Cash flow

See full

Operating cash flow-$13.1M+35.5%

CapEx$86.0K-70.4%

Free cash flow-$13.1M+36.0%

Valuation

See full

Market cap$1.91B+309%

Enterprise value$1.85B+352%

Returns & leverage

See full

Return on equity-28.3%—

Debt / equity0×0.0×

Current ratio27.1×-3.9×

Where this comes from

Reported directly by Rapport Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Rapport Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapport Therapeutics, Inc.'s preferred stock.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Rapport Therapeutics, Inc.'s preferred stock?: Rapport Therapeutics, Inc. (RAPP) reported preferred stock of $0 in Q1 2026.
What does preferred stock mean?: Equity securities with priority over common stock for dividends and liquidation proceeds, but typically without voting rights.